Simphotek

Executive Summary

Simphotek is a US-based medical device company specializing in computational treatment planning and real-time dosimetry for Photodynamic Therapy (PDT). Its flagship product, Dosie™, integrates light distribution simulation and drug toxicity modeling to personalize light-based cancer treatments, aiming to improve outcomes for cancers such as mesothelioma and malignant central airway obstruction. By offering a less toxic alternative to radiation, Simphotek addresses a critical need in oncology, particularly for patients with limited treatment options. The company was founded in 2006 and is currently in the Phase 1 stage, with its proprietary technology positioned to disrupt the PDT market by enabling precision medicine in light-based therapies. The PDT market is growing, driven by demand for minimally invasive cancer treatments. Simphotek's Dosie™ platform has the potential to differentiate itself through real-time adaptive dosimetry, which could significantly enhance treatment efficacy and safety. As the company progresses through clinical validation, its primary challenges include regulatory clearance and adoption by clinical centers. With a strong foundation in computational modeling and a clear value proposition, Simphotek is well-placed to capture a share of the oncology treatment planning market, provided it successfully navigates upcoming milestones.

Upcoming Catalysts (preview)

• Q1 2027FDA 510(k) clearance for Dosie™60% success
• Q4 2026Initiation of pivotal clinical trial for mesothelioma50% success
• Q2 2027Strategic partnership with major oncology device company40% success